Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes

References

• Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720–1732. doi:10.1056/NEJMoa150434726510021
   PubMed Web of Science ®Google Scholar
• Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–78. doi:10.1136/bmj.38678.389583.7C16371403
   PubMed Web of Science ®Google Scholar
• Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–841.21366474
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378(9786):156–167. doi:10.1016/S0140-6736(11)60698-321705063
   PubMed Web of Science ®Google Scholar
• Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):951–964. doi:10.1016/S2213-8587(17)30327-329079252
   PubMed Web of Science ®Google Scholar
• Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–154.23796131
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.18539916
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.31497854
   PubMed Web of Science ®Google Scholar
• Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis. JAMA Cardiol. 2017;2(12):1332–1340. doi:10.1001/jamacardio.2017.419129117273
   PubMed Web of Science ®Google Scholar
• Malik S, Budoff MJ, Katz R, et al. Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi-ethnic study of atherosclerosis. Diabetes Care. 2011;34(10):2285–2290. doi:10.2337/dc11-081621844289
   PubMed Web of Science ®Google Scholar
• Shaikh K, Li D, Nakanishi R, et al. Low short-term and long-term cardiovascular and all-cause mortality in absence of coronary artery calcium: a 22-year follow-up observational study from large cohort. J Diabetes Complications. 2019;33(9):616–622. doi:10.1016/j.jdiacomp.2019.05.01531278061
   PubMed Web of Science ®Google Scholar
• Valenti V, Hartaigh BÓ, Cho I, et al. Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients. Circ Cardiovasc Imaging. 2016;9(2):e003528. doi:10.1161/CIRCIMAGING.115.00352826848062
   PubMed Web of Science ®Google Scholar
• Hallas J, Hellfritzsch M, Rix M, Olesen M, Reilev M, Pottegård A. Odense pharmacoepidemiological database: a review of use and content. Basic Clin Pharmacol Toxicol. 2017;120(5):419–425. doi:10.1111/bcpt.1276428164442
   PubMed Web of Science ®Google Scholar
• Lindholt JS, Rasmussen LM, Søgaard R, et al. Baseline findings of the population-based, randomized, multifaceted Danish cardiovascular screening trial (DANCAVAS) of men aged 65–74 years. Br J Surg. 2019;106(7):862–871. doi:10.1002/bjs.1113530919411
   PubMed Web of Science ®Google Scholar
• Kvist TV, Lindholt JS, Rasmussen LM, et al. The dancavas pilot study of multifaceted screening for subclinical cardiovascular disease in men and women aged 65–74 years. Eur J Vasc Endovasc Surg. 2017;53(1):123–131. doi:10.1016/j.ejvs.2016.10.01027890524
   PubMed Web of Science ®Google Scholar
• Ibrahim NE, Januzzi JL Jr. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018;123(5):614–629. doi:10.1161/CIRCRESAHA.118.31270630355136
   PubMed Web of Science ®Google Scholar
• Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–2791. doi:10.1093/eurheartj/ehx39128886619
   PubMed Web of Science ®Google Scholar
• Paulsen NH, Carlsen BB, Dahl JS, et al. Association between aortic valve calcification measured on non-contrast computed tomography and aortic valve stenosis in the general population. J Cardiovasc Comput Tomogr. 2016;10(4):309–315. doi:10.1016/j.jcct.2016.05.00127247181
   PubMed Web of Science ®Google Scholar
• Bombelli M, Facchetti R, Cuspidi C, et al. Prognostic significance of left atrial enlargement in a general population: results of the PAMELA study. Hypertension. 2014;64(6):1205–1211. doi:10.1161/HYPERTENSIONAHA.114.0397525201892
   PubMed Web of Science ®Google Scholar
• Fredgart MH, Carter-Storch R, Møller JE, et al. Measurement of left atrial volume by 2D and 3D non-contrast computed tomography compared with cardiac magnetic resonance imaging. J Cardiovasc Comput Tomogr. 2018;12(4):316–319. doi:10.1016/j.jcct.2018.04.00129666031
   PubMed Web of Science ®Google Scholar
• Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–644. doi:10.1056/NEJMoa180025630110583
   PubMed Web of Science ®Google Scholar
• Shrivastava SR, Shrivastava PS, Ramasamy J. Role of self-care in management of diabetes mellitus. J Diabetes Metab Disord. 2013;12(1):14. doi:10.1186/2251-6581-12-1423497559
   PubMedGoogle Scholar
• Crocker JC, Ricci-Cabello I, Parker A, et al. Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ. 2018;363:k4738. doi:10.1136/bmj.k473830487232
   PubMed Web of Science ®Google Scholar
• Turrini F, Scarlini S, Mannucci C, et al. Does coronary atherosclerosis deserve to be diagnosed early in diabetic patients? The DADDY-D trial. screening diabetic patients for unknown coronary disease. Eur J Intern Med. 2015;26(6):407–413. doi:10.1016/j.ejim.2015.05.00626058988
   PubMed Web of Science ®Google Scholar
• Lièvre MM, Moulin P, Thivolet C, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials. 2011;12(1):23. doi:10.1186/1745-6215-12-2321269454
   PubMed Web of Science ®Google Scholar
• Faglia E, Manuela M, Antonella Q, et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J. 2005;149(2):e1–6. doi:10.1016/j.ahj.2004.07.027
   PubMed Web of Science ®Google Scholar
• Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301(15):1547–1555. doi:10.1001/jama.2009.47619366774
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, Lappe DL, Lima JA, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014;312(21):2234–2243. doi:10.1001/jama.2014.1582525402757
   PubMed Web of Science ®Google Scholar
• Clerc OF, Fuchs TA, Stehli J, et al. Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging. 2018;19(8):838–846. doi:10.1093/ehjci/jey01429452348
   PubMed Web of Science ®Google Scholar
• Rados DV, Pinto LC, Leitão CB, Gross JL. Screening for coronary artery disease in patients with type 2 diabetes: a meta-analysis and trial sequential analysis. BMJ Open. 2017;7(5):e015089. doi:10.1136/bmjopen-2016-015089
   Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477.31504439
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860.19482214
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024–1031. doi:10.1001/archinternmed.2010.18220585067
   PubMedGoogle Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa161566428304224
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa160382727295427
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa150472026378978
   PubMed Web of Science ®Google Scholar